Teva cozaar tablets

Hello

2024.06.07 14:55 Heavyweightszz Hello

Hello
DM me I’m your savior
FYI real farmapram does not suck.
Btw check dates of all my scripts.
Addys 30s 10s
Xanax 2mg
Vyvanse 40mg
Roxycodone 5mg
submitted by Heavyweightszz to AdderallAdvocatez [link] [comments]


2024.06.05 05:38 primerr69 Some one posted there cancer drugs. 400 a pill. I’m sitting on a gold mine.

Some one posted there cancer drugs. 400 a pill. I’m sitting on a gold mine. submitted by primerr69 to interestingasfuck [link] [comments]


2024.06.02 13:06 HotSarcasm $TEVA: Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024

Nearly 98% of patients experience quality of life impact as a result of tardive dyskinesia (TD) including social, psychological, physical and recreational aspects of daily living
Data highlight for the first time that TD has a multidimensional impact on patients including those with mild TD severity
IMPACT-TD Registry is the largest-ever study of its kind evaluating the holistic effects of TD over three years along with real-world treatment patterns and outcomes with once-daily AUSTEDO® XR (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO® (deutetrabenazine) tablets
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, reinforcing that TD has a wide-reaching, multidimensional impact on patients’ quality of life. These interim findings from the IMPACT-TD study were presented at the 2024 Psych Congress Elevate Annual Meeting, taking place from May 30 – June 2 in Las Vegas, Nevada.
“TD can be a devastating setback for those who have achieved mental stability with their psychiatric medication,” said Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva. “These interim findings from IMPACT-TD Registry, the largest study of its kind, reveal the profound effect that TD can have on a patient’s life, beyond the clinic. Understanding the full impact of TD and how approved treatment options for TD, like once-daily AUSTEDO XR and twice-daily AUSTEDO, can help treat the condition is critical to improving outcomes for patients and is a driving force in our unwavering commitment to developing meaningful solutions for them.”
The two-part IMPACT-TD study is a 3-year longitudinal observational study evaluating how TD progresses over time and impacts a patient’s quality of life (Part A), as well as outcomes related to treatment with once-daily AUSTEDO XR and twice-daily AUSTEDO (Part B).
Clinician-reported TD severity and impact is assessed using the IMPACT-TD scale, the AIMS (Abnormal Involuntary Movement Scale) and the CGIS-TD (Clinical Global Impression of Severity of TD) scale. The interim analysis includes 286 patients with varying levels of TD severity and highlights, for the first time, that clinicians reported that TD has a multidimensional impact, even on patients with mild TD severity. Clinician-reported IMPACT-TD findings show:
98% of patients experience the impact of TD in some aspect of their quality of life
83% of patients experience moderate to severe impact across various quality of life domains, including social (59%), psychological/psychiatric (70%), physical (53%) and vocational/educational/recreational (57%)
54% and 61% of patients with “very mild” and “mild” TD severity based on CGIS-TD, respectively, experience moderate to severe impact on their quality of life
Patient-reported TD impact is assessed using the novel IMPACT-TD PRO (IMPACT-TD Patient-Reported Outcome) scale. Patient-reported findings, as assessed with the IMPACT-TD PRO, show:
59% and 57% of patients reported that TD caused embarrassment in social situations and impacted their ability to enjoy the things they do for fun, respectively
43% of patients reported that TD impacts their sleep
38-42% of patients reported experiencing the physical impact of TD, including on their ability to hold things, do chores and exercise
“These data provide a clearer understanding as to how the abnormal movements of TD significantly impact the daily functioning of patients that cannot be gleaned from looking solely at the severity of the movements,” said Richard Jackson, MD, an Assistant Clinical Adjunct Professor in the University of Michigan School of Medicine’s Department of Psychiatry and the study’s lead investigator. “TD can impact all domains of daily functioning including social, psychological, physical, occupational and recreational aspects of daily living even when the abnormal movements appear to be mild. This emphasizes the need for all clinicians to assess not only the severity of a patient’s TD movements but the impact those movements can have on all aspects of life. Continuing to understand the multifaceted impact of TD and finding ways to alleviate these burdens is crucial to supporting patients on their TD journey.”
Also presented at Psych Congress Elevate 2024 were data supporting:
The development and internal validation of the IMPACT-TD PRO scale, suggesting that the questionnaire can effectively and reliably characterize the multidimensional impact of TD in adult patients.
Final results from the TD cohort of the Phase 4 START study, which investigated real-world treatment outcomes for patients starting AUSTEDO with the 4-week Titration Kit. These full START results show that the titration kit successfully helped patients with TD find individualized therapeutic AUSTEDO doses with effectiveness similar to that observed in the pivotal clinical trials, with high adherence and patient satisfaction rates.
Findings from a retrospective study comparing healthcare resource utilization (HCRU) in patients with TD treated with benztropine versus non-treated patients with TD suggest that benztropine can result in potential harm and increased cost for the patient if used off-label for the treatment of TD.
FULL RELEASE: https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2024/Teva-Presents-First-Real-World-Data-from-the-IMPACT-TD-Registry-Study-at-Psych-Congress-Elevate-2024/default.aspx
submitted by HotSarcasm to TevaPharmaceutical [link] [comments]


2024.06.01 01:54 Intrepid_Night7829 Fake tranq accords going around the UK. I sent them to get tested. Someone even made a video online using my test results to spread awareness. Thanks to that person. My friend sent me a screenshot of the video, same date, postcode and reference as the ones i sent. Be careful.

Fake tranq accords going around the UK. I sent them to get tested. Someone even made a video online using my test results to spread awareness. Thanks to that person. My friend sent me a screenshot of the video, same date, postcode and reference as the ones i sent. Be careful.
Idk why the guy who posted the vid said looks like someone used inspect element. Or whoever added that writing that was just the screenshot I got sent the screenshot of the vid so I didn't add that writing. Idek what that means lmao. But I sent them to a lab and got xylazine test strips, both came back positive.
Just be careful, idk who the seller is apart from they sell in bulk and sell alot of them in the UK. My friend is trying to track whoever it is down. And I'm trying to spread awareness because alot of people are buying them.
Please be careful.
About a month or two ago my friend brought 100 boxes of what appeared to be accord codeine phosphates. He had the intention to make lean out of them. I'm a regular user of codeine and Dhc as I use them for pain, I was prescribed codeine for a long time before starting DHC and used to regularly get boxes off someone who goes to the same pharmacy as me as they don't need them and I use them for pain.
My friend said he had got a good deal and sold me a box before selling to anyone on a larger scale. Me and him both tried them. I noticed the boxes were a bit off, and the tablets were huge in comparison to usual codeine phosphates. However the expiry date was this year, so we thought maybe they were just old and accord had changed the size and look of the pills. I also noticed they dissolved very quickly.
I tried my normal dose, which is usually around 10-14(maximum metabolized amount you can take at once). I'm on DHC which is 2× as potent so 14×30mg codeine phosphates normally doesn't do much but stop Abit of pain and give me a histamine response. I thought they looked off but I was in withdrawal so I just didn't think and wanted to be out of it.
However I noticed I was having weird hallucinations and felt incredibly weird and sleepy. I ended up blacking out, so I knew they were off and immediately told him. But I had not slept in 24hrs so I said it could be that. But just Incase I sent them to a lab to get tested and got xylazine test strips. And it turns out they were just xylazine and nothing else. I was dumb stuck, I didn't think tranq would be in the UK, let alone in codeine which is normally easily available. They are in strips, the strips look 100% perfect apart from the pill sizes. No imperfections. And they came in boxes that were sealed. I sent 2 boxes to get tested and every pill was the same result.
The vendor, who is in the UK is apparently an old guy who gets a lot of prescriptions and had an 'old supply'. He's selling these boxes in bulk, to loads of people. And the normal person who does not use often would not be able to tell unless you are a regular user of codeine.
You can see my results on wedinos type in reference code : W051815.
Before I even checked my results my friend saw someone made a video sharing my results, same reference code, same postcode and same date I put on the form. Whoever that is who made that vid, thankyou.
I'm now trying to spread awareness to people. I never thought it would get to the point where we have fake codeine in the UK, fakes in strips that look legitimately pharma unless you know what the pills from accord exactly look like.
So if you get any accord codeine, that has a C imprint on one side and a 30 imprint on the other be careful. A simple test would be to place a pill in legit like 2ml of water and it'll instantly dissolve.
So please, make sure your getting real codeine. You can check for reference what they should look like. You even better be careful buying lean. As someone unknowingly could have brought them to make lean with. If you buy homebrew in the UK and it makes you feel off, or incredibly sleepy, or Abit like ketamine but with an awful feeling be careful. Buy test strips.
Luckily I can get real codeine from a person who goes to the same pharmacy as me. But others might not be so lucky. Not all codeine or homebrew is fake. My friend has chucked his supply, took the loss and is now only getting from trustworthy sources just for a more expensive price.
There is still legitimate codeine out there, but please just be careful, especially with accords. My friend just resulted to buying Tevas and BP, and all have been legitimate and also tested. So not everything is fake but be weary.
Unfortunately there are people who make fake stuff that looks real for a quick buck. We've been trying to track down the supplier because he's selling loads and loads of these in the UK.
If anyone wants to PM for pics of the fakes to check thats ok with me.
submitted by Intrepid_Night7829 to NovelOpioids [link] [comments]


2024.06.01 01:54 Intrepid_Night7829 Fake tranq accords going around the UK. I sent them to get tested. Someone even made a video online using my test results to spread awareness. Thanks to that person. My friend sent me a screenshot of the video, same date, postcode and reference as the ones i sent. Be careful.

Fake tranq accords going around the UK. I sent them to get tested. Someone even made a video online using my test results to spread awareness. Thanks to that person. My friend sent me a screenshot of the video, same date, postcode and reference as the ones i sent. Be careful.
Idk why the guy who posted the vid said looks like someone used inspect element. Or whoever added that writing that was just the screenshot I got sent the screenshot of the vid so I didn't add that writing. Idek what that means lmao. But I sent them to a lab and got xylazine test strips, both came back positive.
Just be careful, idk who the seller is apart from they sell in bulk and sell alot of them in the UK. My friend is trying to track whoever it is down. And I'm trying to spread awareness because alot of people are buying them.
Please be careful.
About a month or two ago my friend brought 100 boxes of what appeared to be accord codeine phosphates. He had the intention to make lean out of them. I'm a regular user of codeine and Dhc as I use them for pain, I was prescribed codeine for a long time before starting DHC and used to regularly get boxes off someone who goes to the same pharmacy as me as they don't need them and I use them for pain.
My friend said he had got a good deal and sold me a box before selling to anyone on a larger scale. Me and him both tried them. I noticed the boxes were a bit off, and the tablets were huge in comparison to usual codeine phosphates. However the expiry date was this year, so we thought maybe they were just old and accord had changed the size and look of the pills. I also noticed they dissolved very quickly.
I tried my normal dose, which is usually around 10-14(maximum metabolized amount you can take at once). I'm on DHC which is 2× as potent so 14×30mg codeine phosphates normally doesn't do much but stop Abit of pain and give me a histamine response. I thought they looked off but I was in withdrawal so I just didn't think and wanted to be out of it.
However I noticed I was having weird hallucinations and felt incredibly weird and sleepy. I ended up blacking out, so I knew they were off and immediately told him. But I had not slept in 24hrs so I said it could be that. But just Incase I sent them to a lab to get tested and got xylazine test strips. And it turns out they were just xylazine and nothing else. I was dumb stuck, I didn't think tranq would be in the UK, let alone in codeine which is normally easily available. They are in strips, the strips look 100% perfect apart from the pill sizes. No imperfections. And they came in boxes that were sealed. I sent 2 boxes to get tested and every pill was the same result.
The vendor, who is in the UK is apparently an old guy who gets a lot of prescriptions and had an 'old supply'. He's selling these boxes in bulk, to loads of people. And the normal person who does not use often would not be able to tell unless you are a regular user of codeine.
You can see my results on wedinos type in reference code : W051815.
Before I even checked my results my friend saw someone made a video sharing my results, same reference code, same postcode and same date I put on the form. Whoever that is who made that vid, thankyou.
I'm now trying to spread awareness to people. I never thought it would get to the point where we have fake codeine in the UK, fakes in strips that look legitimately pharma unless you know what the pills from accord exactly look like.
So if you get any accord codeine, that has a C imprint on one side and a 30 imprint on the other be careful. A simple test would be to place a pill in legit like 2ml of water and it'll instantly dissolve.
So please, make sure your getting real codeine. You can check for reference what they should look like. You even better be careful buying lean. As someone unknowingly could have brought them to make lean with. If you buy homebrew in the UK and it makes you feel off, or incredibly sleepy, or Abit like ketamine but with an awful feeling be careful. Buy test strips.
Luckily I can get real codeine from a person who goes to the same pharmacy as me. But others might not be so lucky. Not all codeine or homebrew is fake. My friend has chucked his supply, took the loss and is now only getting from trustworthy sources just for a more expensive price.
There is still legitimate codeine out there, but please just be careful, especially with accords. My friend just resulted to buying Tevas and BP, and all have been legitimate and also tested. So not everything is fake but be weary.
Unfortunately there are people who make fake stuff that looks real for a quick buck. We've been trying to track down the supplier because he's selling loads and loads of these in the UK.
If anyone wants to PM for pics of the fakes to check thats ok with me.
submitted by Intrepid_Night7829 to NovelOpioids [link] [comments]


2024.05.31 22:25 kokopelleee Grand Canyon Rim-to-Rim-to-Rim, May 2024

I'm not one to carry a GoPro, take many pictures, or train for an event, but I like writing things up after. It's old school, but the stream-of-consciousness, no edits style can be fun and raw. An old, broken body will always voice it's displeasure, and that's part of the fun too.
Wednesday, May 22nd , 2024 to Thursday, May 23rd, 2024
45.3 miles
10,710 feet of descent (that be the downhill parts)
10,310 feet of ascent (that be the uphilly parts)
Route: start on South Rim,
down South Kaibab (7.4 miles, 4,700’ descent)
up North Kaibab (13.6 miles, 5,695’ ascent) arriving at North Rim
down North Kaibab (13.6 miles, 5,695’ descent) (wow, you go back and forth on the same trail and the distance and elevation match)
Up Bright Angel (9.5 miles, 4,314’ ascent, arriving back at the South Rim
Don’t @ me that those numbers are a little off… I used Phantom Ranch as my trail start/terminus because that’s where I stopped.
A little background, in 2019 I did Rim-to-River-to-Rim with my good friend. At Phantom Ranch, I seriously asked if we could just keep following the North Kaibab trail and do what we really wanted to do: Rim-to–Rim-to-Rim, but wiser heads prevailed. That was my friend, not me. Ever since, I’ve been thinking about doing the double crossing of the Canyon in a non-stop, or non-camping, manner. Why? Because that’s how I wanted to do it.
Wednesday I caught a flight into Phoenix, grabbed my rental car and shot north to the Canyon, arriving around 5pm at my hotel in Tusayan, the hotel and restaurant town a few minutes outside of the park. Check in was easy. I had stopped on the way to get a couple gallons of water and a Subway sandwich for the trail, so I did not need to grab dinner. After loading, and weighing, my pack (new CamelBak Octane with my old 3 liter reservoir) I ate ½ of the sandwich and made a few calls. Yes, my pack was definitely overdone. There was no need for 13 pounds.
Thanks subway staff! They got the bread wrong, and it tasted terrible. Of course I would still carry the other ½ sandwich into the Canyon with me, but I knew I wouldn’t eat it.
After closing the blinds and setting an alarm, I laid out for a little pre-event sleep. Thankfully I was able to get an hour or so of a nap in before my alarm barked at me at 8:50pm. By 9:15 I was on my way into the Park, and by 9:30 I had parked, walked to Bright Angel Lodge and called the park taxi. I’d recently learned that there was a Park taxi (only one of them), and they can take directly to the South Kaibab trailhead which is not accessible to normal vehicles. After waiting a while to get slotted, I was given a “be ready in 20 minutes” from the dispatcher. Inside the hotel lobby it was warm and not windy (that’s what real authors call “foreshadowing”).
A guy about 10 years older than me was in the lobby waiting for his daughter to drive her car up and get him. They had done Rim-to-Rim that day (North to South), and he was hurting bigtime. He mentioned more than a few times how the footing on the North Kaibab trail was terrible. Yes, backcountry trails on steep terrain are always pretty terrible. It’s ain’t a bike path. They rolled out, and I waited a bit longer until I saw the taxi arrive.
As is always the case, delays are real and always happen. There were supposed to be 2 other people being picked up, but they were nowhere to be seen. We waited, the taxi driver ranted, until I suggested we had waited long enough and hit the road. Driver guy had had one hell of a full-moon night and we chatted while he observed the speed limits of 15mph and 25mph very carefully. The roads were deserted at 10:15pm, but he said he was GPS monitored on speed which I can understand. He rolled right up to the trailhead, dropping me off, and picking up another hiker up who had been waiting for up to an hour. It was very, very windy, lots of dust in the air, a bit of sandblasting, but such is life. I had my Marmot rain shell on which I always wear or carry and headed straight for the trailhead.
I had turned on and started the GPS tracker that I had borrowed, so the only pause was to take a picture of the trailhead.
Hoping to get out of the wind, or that it might slack off the lower I got I started heading down the trail. SK is pretty steep, but the wind was not quick to abate. During my last trek here, I had shed my rain shell very early. Today I was going to keep it on for protection from the flying dust and debris.
A few switchbacks down I spotted some lights below me. Cool, someone to catch. Yes, I’m externally motivated. It’s not the best way to live, but it’s who I am.
The switchbacks kept coming, as did the log ladders and mixed trail terrain. Some sections were runnable, so I did. The switchbacks that hit at exposed peaks were definitely a sketchy. With massive dropoffs on either side and wind gusts that rocked the body, these points required some thought. Mainly that thought was “crouch down, so that you don’t get blown over the side to your death.” The darkness exacerbated the fear of falling to my demise. It wasn’t that bad, but mentally, and being alone, it was a thought I couldn’t shake.
At some point I caught up to the couple ahead of me, said a few greetings and scooted past. They had trekking poles and were navigating the uneven trail a bit slower than I was. In the darkness I missed Ooh-Ahh point and it’s famous view. Granted, there’s not much to see in the dark anyway. I had picked a full moon for my trek, but it was not illuminating much. I tried turning my headlamp off a few times because I love trekking by moonlight, but the shadows were too dark and hid critical details that could easily lead to a twisted ankle or maybe worse (steep terrain, dropoffs, ….. You get the picture). I wanted to get rid of my jacket, but was getting buffeted still and decided it was not quite the right time even though I was heating up.
I was doing my usual sipping frequently from my camelbak reservoir and it felt like I was stopping to pee every 5 minutes. That was concerining because it was coming out very clear which is a sign that fluids are passing right through.
At some point, I braked to a complete stop, having spotted a HUGE scorpion just resting in the middle of the trail. I am no fan of those critters, but it was easy to step over. Back to losing elevation I went. I don’t know where I was exactly, I had shot through Cedar Ridge and around Skeleton point where it opens up a bit I noticed a Katadyn 1 liter Be Free water pouch with filter. Both to keep the trail clean and, why not, I picked it up, drained it, and stuffed it in my pack. I already had one just in case I needed to filter water, but a spare doesn’t hurt. Whoever had lost it was well off trail by then and not coming back for it.
Finally I was able to shed my jacket, while moving, which felt amazing.
Turning one corner, I noticed even more lights below me that led to believe there were a few more people on trail below me. There was not, as I’d learn later, but it would have been nice had there been.
Soon I hit the junction with the River Trail which felt pretty soon. Then I was really shocked to come up to the tunnel at Phantom Ranch Bridge (or black bridge as some call it). I was really shocked. I’d been on trail for about 2 hours but didn’t think I’d come this far as mainly I’d just been putting one foot in front of the other and and making forward progress. This was a cool boost!
I crossed the bridge and headed with the flow of the river toward Bright Angel Campground and Phantom Ranch. At Phantom, I topped off my water reservoir and hopped back on trail within a few minutes. It was dark, the air was cool, and life was good. Why not make time?
Heading out of Phantom the trail did what it does and started moving upwards again. About the first half (7’ish) miles of North Kaibab trail are more gradual with 4% to 7% grades which is where one can put some miles in. The longest section of the trail without services is between Phantom Ranch and Cottonwood campground which are a little less than 7 miles apart. This is also the hottest part of the trail during the day. Several miles are in between towering cliffs where the heat has nowhere to go, this section is called “The Box.” Of course, at 1am, it wasn’t hot at all. The full moon was providing some super cool illumination on the cliffs, but I still needed my headlamp for trail details. Just above the box, there was a stream in the middle of the trail which I avoided. Wet feet can be the end of a hike. A few hundred feet up, it was clear that it wasn’t a stream but a break in the water line.
Uh-oh. The water line supplied the North side water stops. Would they now be shutoff?
I was still making good time and decided that, even with the waterline break, I would skip refilling at Cottonwood and go the next 1.4 miles up to Manzanita rest stop to refill. Made it to Manzanita and the water was still on, so I quickly refilled my reservoir and got back on trail. Now it was steep again with an 11% grade. I was thinking longingly of the 7 mile stretch between Cottonwood and Phantom Ranch and how nice it would be to jog that section once I returned to it later in the day. I still think it would be nice to jog that section someday.
I was starting to see headlamps above me from the people who had done an early start on their Rim-to-Rim treks staring from the North Rim. I loved the solitude of being alone in a very popular national park, but it’s also good to know that a few people are around.
I have read different numbers, but it is said that out of 4.75 Million people who visit the Grand Canyon every year, only 5% go below the rim (at all) and less than 10% of those folks make it to the river. That would be about 0.5% of visitors make it Rim-to-River-to-Rim or Rim-to-Rim. I can’t find any data on who many people do double that up and do Rim-to-Rim-to-Rim on any given year.
Let’s divert a bit and talk about how this can be done… Yes, there are many options. Some people hike straight through, they leave the North Rim in the dark and traverse to the South Rim over the course of 10-20 hours. Another choice is to overnight camp along the way at one of several campgrounds (reservations REQUIRED). I’m not against the concept, but the thought of carrying a tent and sleeping bag up the other side of the canyon sounds way too hard to me. Yet another choice is to reserve a cabin at Phantom Ranch where you can also get dinner and breakfast. Because it is a cabin, you don’t have to haul camping gear.
Speaking of Phantom Ranch, they do sell a few things to hikers including ice cold lemonade. A lot of people talk about it like it’s an elixir from the gods. Personally I would prefer to keep walking and not waste time stopping, buying and drinking something that needs to have it’s cup recycled at the location.
Back on trail, it was good to see people. Most honored trail etiquette - whoever is going uphill has the right of way, so I got to keep plugging along. It was finally light, and I was able to ditch my headlamp finally which was lovely. Up, up, up, I went. Seeing many folks who had questions, “when did you start?” “how are you doing?” and the obligatory “You’re ALMOST there!”
Note to the trail gods, I was NOT “almost there.” It was nice for folks to say it, but after every group said it, and I could see at least 1,000’ vertical to gain I started thinking “Do they think that I am almost there, or are they being incredibly nice?”
Answer: they were being nice.
At this point, the trail had more and more major step ups and log ladders, and my left knee was really hating me. Over the years, my patella, which does not track correctly, has ground away the cartilage from my femur, so any 90deg bend with force causes a massive stab of pain. OK, step ups would only be with my right leg from now on. Plus, as I was gaining altitude it was getting a bit chilly. Keep moving. My sleeveless t-shirt does not provide a ton of warmth.
I had tried to use one of the long-sleeve sun protecting hoodies, but I really didn’t like it. It just wasn’t for me. Another tangent, so much of this stuff is personal. What gear do you bring, what shoes do you wear, how many layers do you bring, what do you eat? It’s all a matter of trial and error.
At some point, I came across a group of Chinese couples who were descending for their R2. The guy at the lead of their pack asked me a few questions and finally asked “are you doing R3?”
“Uhhhh, yeah. At least I’m hoping to. Need to finish Rim-to-Rim first.”
For years I did not bring people in. I had a “NOBODY CARES. WORK HARDER” sticker in huge letters on my handstand pushup wall. After a lot of work on myself, it turns out that A LOT of people care. Even strangers from another country can care. The lead guy yelled back to the rest of their crew who congratulated me with every person I walked past. It was pretty cool.
The trail though? It didn’t care. It just kept going uphill.
Not too far from what really was the end, there was crew of about 5 guys who took up most of the trail and refused to share. There are always those folks out there. Everyone else was cool as heck.
And then… the final stretch, well, for this section, and I was at the North Rim. It was cold. I didn’t need water, so I took my selfie at the North Rim sign, used the GPS personal locator to send an “I’m OK” message and went back down the trail.
Unfortunately, my legs were more than a bit wrecked. That I could only step up with my right leg meant I could also only lower myself with my right leg when there were rocks and logs to step down from, and the muscles along my left shin were screaming in pain too. I was good and assessed if this meant I should call it a day and try to get a shuttle to the South Rim, but I could still move even if only slowly.
Down we go again… Step downs were not fun. Plant right foot, pivot on it, lower left leg to the ground below, repeat, repeat, repeat. Oh, and blisters were cropping up too. There is a water filling stop at Supai tunnel which I targeted for my refill and blister treatment. Once I covered the 1.7 miles to the tunnel, I took a break, pulled off my pack and dug out my blister kit.
I say “dug out,” but the Octane pack is pretty well organized. I simply located the blister kit in the little internal pouch, pulled out the tiny scissors and started lancing blisters. One circled the back of my heel where the insole ended. 20 miles to go and now my shoes finally show their true colors. After refilling my water and bandaging my blisters, I got back to what needed to be done, losing elevation. Damn I was going slow though. Way too slow but having to walk differently to avoid pain was a slow process.
I’ve done it many times before in many situations. There was no danger, I had food and water and was regularly ingesting salt tablets. It’s a mind-game now. The plans I had roughly sketched out where out of the window, and it would be a day of slow and steady progress.
The trail and terrain look so different coming down than going up and not just because there was now light to see.
As with all alpine type trails, distances are weird. I saw a building below me which I thought was the Manzanita rest stop, and it looked very close. Problem was, it was not the Manzanita rest stop, and to get to it required a lot more switchbacks and uneven terrain. It’s almost sad when you realize it’s a building I couldn’t have seen in the morning on the way up.
Around now, more people were coming up the trail too, doing a South to North version of Rim-to-Rim, with a few doing R3. Also came across a guy lugging a mountain bike across the Grand Canyon, because the Canyon is part of the Arizona Trail. You can’t ride a mountain bike through the canyon, so, if you are doing the AZ trail by mountain bike, you have to carry it across. That’s hardcore.
I passed a few R2 hikers, even in my slow state there are always folks moving slower, and heard some people talking behind me. I have a fragile ego and didn’t want to get passed this close to Manzanita rest stop, so I picked up the pace a bit. By “a bit” I only mean 1-2%. I wasn’t winning any prizes today. Thankfully, Manzanita appeared, and I was able to hop off the trail before getting passed. I said it, and I meant it. I have a fragile ego.
The two guys also hopped in to the rest stop. One taking the seat next to me at the picnic table and immediately pulling his pants off.
OK, he had running shorts underneath, but that did not stop me from remarking “it’s not everyday a guy I don’t know takes his pants off next to me.”
I didn’t need water, but I did use the time to apply a nice layer of sunscreen. The slurry of sunscreen, trail dust, and salt crystals is probably a great sun protection, but it’s kind of gross too. 10 minute break over it was time to get back on trail. I was not happy at this point. I should be able to run some of this, but my legs were not allowing any of that. The 1.4 miles to Cottonwood took just as long going down as they had going up in the morning.
Actually, it was still morning, around 9am or so (?), but I had been going since 10:30pm last night. At Manzanita I used the GPS to message that I was safe (have to say that or people freak out) but struggling and plans have changed. I’d probably be stopping for a while once I got to Phantom Ranch. That lemonade that I had distained earlier was sounding pretty darn good.
It’s pretty wide open at this point with the nothing to block the sun. My boony hat with neck guard was doing a great job of keep my head, neck and face protected, but nothing was protecting me from my slow progress. There were a lot more northbound folks on the traill, and they looked a LOT fresher than I felt. They kept saying “good morning” too which was incredibly surreal. Didn’t they know it was late afternoon already? Except it was not late afternoon.
They guys who had been behind me at Manzanita would leap frog me. They walked faster but took frequent breaks. Soon enough I hit Cottonwood Campground. No need to stop for water, so I kept going. There are a few uphills in this section, and those did not feel fantastic. Again, no danger, no worries, just keep moving the legs.
When I hit the part of the trail with the water line break I knew I was close to the heat of the box. It wasn’t the heat of the day, but it was later than I had hoped to be there. Drink, talk salt tablets, eat as I could, keep plugging.
My only thought when entering the Box was to get through the Box and into Phantom Ranch, which is really close to the end of the Box. The only way to get out of the box is to keep walking, and, at some point, instead of seeing canyon walls, the sky will open up to show the South Rim. Oh hey, the South Rim is 4,000’ vertical above, and will need to be dealt with at some point today. All in it’s time though.
My history of epic events has taught me some very critical lessons: I’m not very smart, and I can dig deep and grind out distance when most people can’t. It’s about turning inward and just making progress when the only thing you can do is make incremental progress.
I was probably down to 1.5 miles per hour now, and that was downhill. Ugh.
Every corner revealed a new section of canyon walls instead of open sky, and the Box was getting warm. Even with the roaring creek beside us this section just held a lot of heat. The trail varied sides of the creek as the 7 bridges criss crossed it. One more bridge down meant a little closer to a long break. More canyon meant another corner to hope to see the South Rim. By now, I was sitting regularly for a break. My legs wanted it, so I gave it to them.
The first deep drink from my camelbak was inevitably hot, and the 2nd and 3rd, which had not been exposed to the sun, were delightfully cool. I was cherishing those 2nd and 3rd sips.
Another corner, and still more canyon walls. In the distance I would see the 2 guys who I’d talked with earlier. They weren’t making that much headway in comparison. At some point, the canyon walls fell away and Phantom Ranch appeared. I really wanted that lemonade.
The steps up to the window counter at Phantom were not nice to me, but I got my lemonade, 2 ice cold apples, and a small bag of peanuts (more salt for the fluid absorption). There was a picnic table, in the shade, so I took it. Sipping lemonade and enjoying a couple of lovely apples.
Given that I had been on trail for 12 or so hours, with no sleep, I decided to set an alarm and take a 30 minute nap. You know you’re tired when you are old and immediately all asleep while laying the bench of an old picnic table.
I woke up when my person lightly scratched their nails on my shin to get my attention.
Except I was doing this solo, how they hell did they get here? Oh, it was a squirrel trying to climb me to get to my apple core. The mind is an amazing thing.
The Chinese crew was at Phantom too, and they were very interested in my condition. They were expats living in Toronto, and we had a nice chat.
After an hour at Phantom it was time to move on again. I wanted to soak my feet and legs in the cold Colorado river, but the Phantom access was upriver, so I targeted the river access that was across the Silver Bridge and up the trail a ways. As I left Bright Angel campground, the “pants off” guy from the duo asked if I had seen his buddy. They had gotten separated.
“You mean your friend with the blue shirt?”
“ummm, I have no idea what color shirt he has on, I’m color blind”
“oh hey! Me too… the dark shirt?”
“Yeah him. He went back to the store for something and hasn;’t come through”
“No, I haven’t seen him”
Crossing the Silver (OK, the “galvanized”) bridge, a couple of motor rafts drifted below. Maybe they had the better way of seeing the Canyon.
I wasn’t emotional at all, no frustration or anger. I knew that my plans were out the window, but the true nature of all of this was in dealing with what is versus what one wanted things to be. The section between Silver Bridge and the river access (before the trail turns left and heads up again) is pretty mellow. The section where the trail is beach sand is a bit challenging. Mainly it was all just warm. Very warm.
At the river access, a construction crew was working with some type of cable. I assume it was massive power cables, so I chose not to do my soak there. I know there are a few places where a creek crosses the trail up ahead. Thankfully there was one just a few yards up, so gladly stopped and dropped my pack. The cold water felt great on my feet and knee, and I took the time to do some more blister surgery.
Unfortunately, as I put on fresh socks, which I had debated about carrying, I knocked my sunglasses into creek which swiftly took them away. It was getting into later afternoon, still sunny, but I hoped I could get by with lowering my hat.
Back on trail, up I went. If I haven’t said “stead motion” a hundred times by now, just wait, I’ll easly get to 100 by the time this over.
The two guys came through this section and rested for a bit and headed out before me
Bright Angel trail is about 10 miles, and it’s roughly divided up into sections. It’s about 5 miles from Phantom to Havasupai Campground (the only water source turned on today), then it’s 1.5 miles to 3 Mile Resthouse, 1.5 miles to Mile-and-a-Half Resthouse (quick, do the math on that…) and then another 1.5 miles to the South Rim. The section to Havasupai was a slow slog. Somewhere on the Devil’s Corkscrew, which is a series of switchbacks that is really visible from above, a guy flew past me wearing full pants, boots, and a firefighter helmet while also holding a radio. It was impressive and disheartening.
The two guys were ahead of me, and I could see them on occasion, never catching up to them.
During the section where the creek runs in the middle of the trail, another shirtless firefighter blew past me. “How far is he ahead of me?” he asked, “I have to catch him.” You go bro.
Surprisingly I caught up to the two guys. We chatted for a bit wondering how much farther Havasupai was. We estimated at last another mile or mile and a half. This is where there is a creek on the South side, and the greenery and animal sounds were amazing. They kept me company as I moved along at my 1.5 mile per hour pace. Then I hit Havasupai, took a seat, took off my hat and pack, and rested.
The Chinese crew was here too as they had left Phantom well before me. The duo arrived too. I rested, filled my water reservoir, ate a little, and rested some more. By now I was using a stop watch to keep track of my stops. I will look at my watch but never remember the time. Seeing “10 minutes” on a stopwatch is much more effective. At 5:40pm, the duo and I pulled on our packs to leave and discussed how much time we had left.
“It’s about 1 ½ miles between each next stop (3 mile, 1 ½ mile, South Rim), with about 1,000 feet of vertical between each. At my pace of 1.5 mph, that’s roughly 3 hours plus stops, so I’m saying 9pm on the Rim”
Hey, I sounded like I knew what I was talking about. Confidence when speaking is critical.
I pulled on my pack and started up the trail. It was now early evening, it was cooling off, and the sun was not beating down. If you are paying attention, I wasn’t, you’ll notice that I forgot something.
About 20 minutes later I realized I had forgotten my hat. Oops, but there was no way I was going back for it. Somebody can get some use out of it. Instead I started thinking about hat shopping. What kind would I replace it with?
I had forecasted an hour of hard hiking between each waypoint, so I used time as my measurement. I should get to 3 Mile at 6:40pm, and I kept looking at my watch as I walked about. 6:01pm. 6:07pm, 6:20pm. Etc. etc. It was my way to guage progress. I also caught and passed the Canadian Chinese crew. 4 married couples who adventured together and trained together. We chatted for a while, but I need to keep my pace. After leaving them a French guy caught up to me “excuse me, did you leave a hat at the water stop?”
Yes, yes, I did.
“My friend is carrying it…” OK, I waited a minute for the friend who handed me my hat and scooted up the trail. No way I was taking my pack off, so I rolled it up and held it in my hand. I really didn’t pause in hiking, did take a short seat a time or two, and at 6:30 the 3 Mile Resthouse’s beauty appeared before me.
Normally when I hike long, my fingers swell significantly. It’s not sodium, it’s that edema pools in my fingers. I had noticed it for most of the day, but it, very surprisingly, had gone away in my right hand. Holding onto my had cleared the edema from my hand. Maybe I should look at getting some decent trekking poles with large grips in order to force my hands to hold something and reduce the swelling?
OK then, making good time all things considered. I went past the resthouse and took a seat on a rock. A young couple I’d been leap frogging with ended their break at the resthouse and started up ahead of me. There was no way I’d be catching them.
Throughout the day, I had noticed one set of shoe prints with a distinct “Adidas” logo, and I started seeing it again. Was it him or her? The dust of the trail held perfect shoe impressions, but only briefly, so it became a game to track the Adidas logo and guess which one of them it was.
You have to do something to pass the time.
It was coming on to to sunset, but this section of the trail isn’t the best aligned for sunset views, so I admired the vistas and searched for shoe prints wil also looking at my watch to see how much of the next hour I had left before I reached Mile and a Half Resthouse.
If you have never done it, pushing forward for literally hours on end is a reward unto itself. It takes WORK to gain 1,000’ of vertical in a mile and a half (approximately an 11% grade). This trail section is better than most with several decent sections, but there are alway log ladders and step ups to overcome. My left leg felt a lot better since soaking in the creek, and I was able to judiciously use in on smaller step ups to save my right leg. For the bigger step ups it was “adjust stride to put left foot at the base of the step up, step up with the right leg, then push myself up and over.”
At 7:30 I hit the Mile and a Half Resthouse, right on my adjusted schedule. After a brief sit, it was time for the final push to the Rim.
I had not seen the duo since Havasupai, and I had managed to catch a couple of people. It wasn’t a lot, but it was still a nice mental boost.
The Bright Angle Tunnel came out of nowehere much to my joy, but I forget that it’s further down trail than I want to admit. There was still time left in my day. Right about then I heard strong footsteps behind me. It was a guy I’d seen a time or two during the day in a party of four. One of their team was hurting, so he was charging ahead to get some food for the guy and bring it back down. That’s impressive.
He also told me that Maswik Lodge has a food court. By now, my thoughts had turned to “what am I going to eat when I’m off this trail, and where can I get some LEMONADE?”
Food court you say??? Hmmmmm.
The guy said we were 3 switchbacks away from the end. Granted, the last switchback is a haul from the trailhead, but it was good info. I came across two women, one of whom had pushed it too hard sensing the end, and was heaving at the side of the trail. They assured me that they had what they needed. OK, the woman who was not heaving assured me that they have fluids and clothing and headlamps after I had checked to see if they needed any help, so I kept moving forward.
Then, there it was, the buildings at the edge of the Rim! 20 hours to the minute instead of what should have been about 17, but life is what you make of it.
I didn’t see the big Bright Angel sign and wanted to get to my car, so I took at quick selfie at the trailhead sign and hoofed it to my rental SUV. it felt sooooooooo nice to take off my running shoes, socks and gaiters and put on my Teva’s. Pure bliss.
Of course I was shivering uncontrollably in the wind and from the exertion. After changing shoes, notifying everyone I was OK, and texting Monika and my kids, it was time to roll. My intent was to get out of the park, but, driving past Maswik, which looked open, I had to stop in. After acquiring 4 slices of cheese pizza I was on my way to my hotel. Stopping at the minimart in Tusayan, I scored a lemonade, a coke, and a Double IPA. All sounded delicious.
The parking lot was full, so I did the back lot which required a set of downstairs to get to my room. That was a challenge.
In my hotel I made a few calls. My 89yo mother had been more than a little worried. My person was incredibly happy for me and also no fan of the GPS tracking software. My kids were cool that I was still breathing. I enjoyed the lemonade and coke, AND the pizza. It wasn’t that great to be honest, but I loved it.
Then I hopped in the showing to erase 20 hours of trail dust and grime. I’m sure the hotel is used to it, but I felt bad that the washcloth was far from white when I was finished. At least I was clean!
And then I slept, and a good sleep it was. So good. 11 hours of bliss.
The next morning I took my time, packed up while drinking coffee, and walked over to the Mexican place next door. It was only 4.0 on Google, but I have rarely met a chimichanga that I don’t like. Deep fried is amazing.
Then I headed back into the park. The line took a bit, but it wasn’t too bad. Plus, my free veteran park pass meant I didn’t have to pay. The main lots were full, so my goal of getting a picture at Mather Point wasn’t going to happen. I was feeling pretty good but not like walking a mile or two. Nor was I interested in riding the park shuttle. A quick stop at the Market Plaza allowed me to find a replacement pair of sunglasses for the drive to Phoenix. Then I drove over and found a hidden parking spot near Bright Angel. I might not have been able to get to Mather Point, but I wanted a couple of daytime pictures.
After that, I pointed the car south, and then west for a visit with my friend Mark and their partner in Prescott. Based on their suggestion, I was able to book a short massage the next day also. Seeing their town, laughing about life, and explaining the fun I had had the day before was a fantastic detour. After my massage, Mark and I grabbed lunch, we were able to swing by Beth’s shop for a goodbye, then I was off for the 2 hour drive to Phoenix airport and my flight home.
Rim-to-Rim-to-Rim is now done.
Will I go back again? Probably. I know a couple of people who are interested in doing Rim-to-Rim, and, well, though the experience has been achieved, and in my core I am entirely an experience junky, there’s that little thing about doing Rim-to-Rim-to-Rim with style, and speed, that is brewing at the back of my mind.
It’s just a little thought though.
At least it’s a little thought for now….
45.3 miles
10,710 feet of descent
10,310 feet of ascent
19 hours and 51 minutes
submitted by kokopelleee to grandcanyon [link] [comments]


2024.05.31 01:40 Panda_MAN420_918 Weekly script of 21-5mg and 21-2mg valium

Weekly script of 21-5mg and 21-2mg valium submitted by Panda_MAN420_918 to benzodiazeland [link] [comments]


2024.05.30 12:47 HotSarcasm $TEVA: Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO XR as a one pill, once-daily treatment option, now with four new tablet strengths (30, 36, 42, 48 mg) indicated in adults for TD and HD chorea.
“Since our launch of AUSTEDO® in 2017, we have been committed to helping people living with TD and HD chorea treat these chronic, involuntary movements,” said Dell Faulkingham, Senior Vice President, Head of U.S. Innovative Medicines at Teva. “AUSTEDO, backed by the longest efficacy and tolerability data to date, has continued to evolve – having received approval for AUSTEDO XR, our once-daily extended-release formulation in February 2023. This latest milestone offers a streamlined treatment regimen for clinically therapeutic doses with the broadest dosing flexibility.”
Currently more than 57 million Americans are living with a mental illness, 14 million of whom are living with a serious mental health condition.6 For those taking certain mental health medications, one in four may experience the onset of TD, an often-overlooked chronic movement disorder that can have a physical, emotional and psychological impact on patients.7,8 HD is a fatal neurodegenerative disease characterized by cognitive deterioration, behavior and/or psychological problems and uncoordinated and uncontrollable movements known as chorea – a symptom that affects 90% of patients.9,10 Both conditions can pose significant challenges to patients’ everyday lives as simple tasks like eating, talking and walking can be impacted.
“Knowing patients living with TD and HD chorea are also managing other underlying concomitant conditions, it is important that treatment options for these chronic movement disorders are not only effective, but keep the patient experience in mind,” said Dr. Rakesh Jain, Clinical Professor of Psychiatry, Texas Tech University School of Medicine. “This latest AUSTEDO XR approval provides patients with the same proven efficacy, but now with the convenience of a one pill, once-daily option for clinically therapeutic doses as established by the pivotal clinical trials to help control involuntary movements that can make carrying out basic daily activities difficult."
Patients with TD taking AUSTEDO XR can expect symptom improvement as early as two weeks while patients with HD chorea may experience a significant reduction in TMC score, with three years of the longest TD and HD chorea clinical trials and sustained results to date.1,2,3,4,5 AUSTEDO XR, along with its twice-daily counterpart, AUSTEDO (deutetrabenazine), are the only VMAT2 inhibitor treatments with no restrictions for use with CYP3A4/5 inducers or inhibitors, an important consideration for patients who take a variety of concomitant medications to manage their underlying conditions.11,12
Approximately 90% of patients with insurance coverage are expected to pay $10 or less for their prescription with financial assistance offerings.1 Teva is committed to helping eligible patients who have been prescribed AUSTEDO XR access their medication. Teva continues to support with access, reimbursement, prescription pull-through and patient assistance. Savings on out-of-pocket costs may vary depending on the patient’s insurance provider and eligibility for participation in the co-pay assistance program. For more information regarding cost and coverage options for AUSTEDO XR through Teva Shared Solutions, visit MySharedSolutions.com.
About Tardive Dyskinesia (TD) Tardive dyskinesia (TD) is a highly debilitating, chronic movement disorder that affects one in four people who take certain mental health treatments and is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact individuals. 13,14,15
About Chorea Associated with Huntington’s Disease (HD) Huntington’s disease (HD) is a fatal neurodegenerative disease characterized by uncoordinated and uncontrollable movements, cognitive deterioration and behavioral and/or psychological problems. Chorea – involuntary, random and sudden, twisting and/or writhing movements – is one of the most striking physical manifestations of Huntington’s disease and occurs in approximately 90% of patients. Chorea can have a significant impact on daily activities and progressively limit peoples’ lives. 9,10
About AUSTEDO XR Extended-Release Tablets and AUSTEDO Tablets AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease. Safety and effectiveness in pediatric patients have not been established. AUSTEDO XR is the once-daily formulation of AUSTEDO.
FULL RELEASE: https://www.businesswire.com/news/home/20240425312754/en/
submitted by HotSarcasm to TevaPharmaceutical [link] [comments]


2024.05.23 11:16 Pizdokleszczu Meds shortage? Teva brand Dexamfetamines

Since February I was tryingto fill my prescriptions in the Boots pharmacy in London. I was told they don’t have Teva brand Dexamfetamines in stock and their supplier also doesn’t have anything in the warehouse so they can’t even order them for me. I was advised to check out independent pharmacies and so I did check a couple of them but without any luck.
Is there really shortage of these meds currently, or maybe I’m just looking in wrong pharmacies? I am prescribed 20mg dex 3x daily and usually with Teva brand I was given plenty of boxes of 5mg tablets (so one dose for me was 4 tablets), as these were the only ones available. They said the 20mg Teva tablets are not available at all, I was fine with the 5mg tablets in higher amounts. However; last time I was given Amfexa which I don’t tolerate quite well. I really need the Teva brand meds. Anybody knows what’s going on and where I should try my luck??? 🍀
submitted by Pizdokleszczu to ADHDUK [link] [comments]


2024.05.14 03:23 TeddyBearOverlord Anyone else get weird side effects from generic Wellbutrin?

Hi guys,
I took Wellbutrin for a brief period of time 5 years ago. The stuff changed my life, but after the prescription ended I decided to try to raw dog life. I unfortunately have found myself in another depressive state and have had to resort to anti depressants once more to keep myself stable, safe and afloat. My doctor prescribed me Wellbutrin, and on the prescription it said the words “Wellbutrin”. No other name, nothing. I even have a picture of it on my phone.
I go to fill out the prescription and the pharmacist asks me if I have any health insurance. I don’t, but I was willing to pay up front for it no matter how much it was. I get my prescription and take it…. 8 hours in I felt like I was going to simultaneously have a heart attack and vomit. I had hot flashes, an accelerated heart beat and nausea with stomach pains and had an anxiety attack.
This was an immediate red flag to me because Wellbutrin has never made me have side effects like that ever in the time I was on it. I read the bottle and realize the word “Wellbutrin” isn’t on it at all. Instead, it read “Teva bupropion”. I search it up and it’s the generic brand.
I was absolutely pissed the pharmacist did this without consulting me or without my consent. I called the pharmacy and asked why I was having all these side effects and the answer I got was “well you shouldn’t be having those side effects”. Great answer, Jack ass. I did some more research and found that these side effects are consistent with Teva Bupropion and that a lot of other people on Wellbutrin haven’t been able to handle the generic brand because it also gives them wierd side effects too.
I just want to know if the pharmacist was gaslighting me because he was a Jack ass for not warning me ahead of time and did this without my knowledge and he’s trying to save his own ass, or if anyone else has had the same experience. It honestly feels like I’ve taken 9 tablets of adderall and I feel like I’m going to die. Is this common?
submitted by TeddyBearOverlord to Wellbutrin_Bupropion [link] [comments]


2024.05.10 06:12 Otherwise_Error3325 All Script.... All Mine!

All Script.... All Mine! submitted by Otherwise_Error3325 to bud_n_pill_lovers [link] [comments]


2024.05.10 00:43 Netdocs Diazepam 10mg 🚀💊

Diazepam 10mg 🚀💊 submitted by Netdocs to esctacy_cloud [link] [comments]


2024.05.09 23:46 Waltersprite_ TEVA FROM FARM TO FORK

TEVA FROM FARM TO FORK
I use teva materials, and make teva pints…
Never once claimed them to be legit, however I do claim them to be honest, clean and pack a punch!!!!
WALTERSPRITE the king of brew…. If you didn’t already know, soon you will!!
submitted by Waltersprite_ to lean365 [link] [comments]


2024.05.09 23:17 RestaurantOk3089 alright here

alright here submitted by RestaurantOk3089 to benzodiazeland [link] [comments]


2024.05.08 19:35 Intelligent-Mud9251 Better than Valium?

Better than Valium?
U tell me
submitted by Intelligent-Mud9251 to bud_n_pill_lovers [link] [comments]


2024.05.08 13:15 HotSarcasm $TEVA: Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook

$TEVA: Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
  • Generics business and AUSTEDO® growth lead Q1 2024 performance.
  • Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023.
  • Generics business growth across all regions – increased by 9% in local currency terms globally, compared to Q1 2023.
  • AUSTEDO – continued growth, up 67% (in the U.S.) from Q1 2023; reaffirming 2024 revenue outlook of ~$1.5 billion.
  • AJOVY® – revenues of $113 million in Q1 2024, up 18% from Q1 2023.
  • Recent FDA approvals of SIMLANDI® and SELARSDI™, biosimilars to Humira® and Stelara®, respectively.
  • Announced positive Phase 3 efficacy results for olanzapine LAI (TEV' 749); no incidence of post-injection delirium/sedation syndrome (PDSS) observed to date.
Q1 2024 Highlights:
  • Revenues of $3.8 billion
  • GAAP loss per share of $0.12
  • Non-GAAP diluted EPS of $0.48
  • Cash flow used in operating activities of $124 million
  • Free cash flow of $32 million
  • Full year 2024 business outlook reaffirmed:
    • Revenues of $15.7 - $16.3 billion
    • Adjusted EBITDA of $4.5 - $5.0 billion
    • Non-GAAP diluted EPS of $2.20 - $2.50
    • Free cash flow of $1.7 - $2.0 billion
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2024.
Mr. Richard Francis, Teva's President and CEO, said, "In 2024 Teva is off to a good start, with global revenues of $3.8 billion showing growth of 5% in local currency terms compared to Q1 2023, fueled by robust growth in our generics business across all regions, and continued growth of our innovative brands AUSTEDO and AJOVY."
Mr. Francis continued, “As we mark the first anniversary of our Pivot to Growth Strategy, I am proud of the significant strides we have been making in realizing the goals and milestones we set out to achieve on our journey to growth, including the progression of our innovative pipeline and growth drivers, as well as the recent FDA approvals of SIMLANDI and SELARSDI, the biosimilars to Humira® and Stelara®, respectively, and the positive Phase 3 efficacy results for olanzapine Once-Monthly LAI announced this morning. The study met its primary endpoint, demonstrating a well-tolerated effective long-acting treatment option for schizophrenia, with no incidence of post-injection delirium/sedation syndrome (PDSS) observed to date. As we continue to accelerate our growth progress, we reaffirm our financial guidance for 2024."
Pivot to Growth Strategy
In May 2023, we introduced our “Pivot to Growth” strategy, which is based on four key pillars: (i) delivering on our growth engines, mainly AUSTEDO, AJOVY, UZEDY® and our late-stage pipeline of biosimilars; (ii) stepping up innovation through delivering on our late-stage innovative pipeline assets as well as building up our early-stage pipeline organically and potentially through business development activities; (iii) sustaining our generics medicines powerhouse with a global commercial footprint, focused portfolio, pipeline and manufacturing footprint; and (iv) focusing our business by optimizing our portfolio and global manufacturing footprint to enable strategic capital deployment to accelerate our near and long-term growth engines and reorganizing certain of our business units to a more optimal structure, while also reorganizing key business units to enhance operational efficiency.
First Quarter 2024 Consolidated Results
The data presented in this press release with respect to operating income (loss), income (loss) before income taxes, income taxes (benefit), net income (loss) attributable to Teva and earnings (loss) per share for prior period has been revised to reflect a revision in relation to a contingent consideration and related expenses. For additional information, see note 1b to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 and note 1c to our consolidated financial statements included in our Quarterly Report on Form 10-Q for the period ended March 31, 2024.
Revenues in the first quarter of 2024 were $3,819 million, an increase of 4% in U.S. dollars or 5% in local currency terms compared to the first quarter of 2023. This increase was mainly due to higher revenues from generic products in all our segments, from AUSTEDO, as well as from AJOVY in our Europe and International Markets segments, partially offset by lower revenues from COPAXONE®, and from Anda, our distribution business in the U.S.
Exchange rate movements during the first quarter of 2024, net of hedging effects, negatively impacted overall revenues by $39 million, compared to the first quarter of 2023. Exchange rate movements during the first quarter of 2024, including hedging effects, negatively impacted our operating income and non-GAAP operating income each by $11 million compared to the first quarter of 2023.
Gross profit in the first quarter of 2024 was $1,771 million, an increase of 12% compared to $1,582 million in the first quarter of 2023. Gross profit margin was 46.4% in the first quarter of 2024, compared to 43.2% in the first quarter of 2023. Non-GAAP gross profit was $1,963 million in the first quarter of 2024, an increase of 9% compared to $1,796 million in the first quarter of 2023. Non-GAAP gross profit margin was 51.4% in the first quarter of 2024, compared to 49.1% in the first quarter of 2023. The increase in both gross profit margin and non-GAAP gross profit margin was mainly due to a favorable mix of products as well as a decrease in our operational costs.
Research and Development (R&D) expenses, net in the first quarter of 2024 were $242 million, an increase of 4% compared to $234 million in the first quarter of 2023, as we continued to execute on our Pivot to Growth Strategy. Our higher R&D expenses, net in the first quarter of 2024, compared to the first quarter of 2023, were mainly due to an increase related to our late-stage innovative pipeline in neuroscience (mainly neuropsychiatry) and in immunology and immuno-oncology. Our R&D expenses, net in the first quarter of 2024 were also impacted by reimbursements from our strategic partnerships.
Selling and Marketing (S&M) expenses in the first quarter of 2024 were $608 million, an increase of 11% compared to the first quarter of 2023 to support our Pivot to Growth strategy, mainly related to commercial activities for AUSTEDO and UZEDY in the U.S.
General and Administrative (G&A) expenses in the first quarter of 2024 were $278 million, a decrease of 6% compared to the first quarter of 2023, mainly due to lower litigation fees in the first quarter of 2024.
Operating loss in the first quarter of 2024 was $218 million, compared to an operating loss of $13 million in the first quarter of 2023. Operating loss as a percentage of revenues was 5.7% in the first quarter of 2024, compared to an operating loss as a percentage of revenues of 0.4% in the first quarter of 2023. The higher operating loss in the first quarter of 2024 was mainly due to higher other assets impairments, restructuring costs and other items, as well as higher S&M expenses in the first quarter of 2024, partially offset by higher gross profit, lower legal settlements and loss contingencies and lower intangible asset impairments in the first quarter of 2024. Non-GAAP operating income in the first quarter of 2024 was $892 million representing a non-GAAP operating margin of 23.4% compared to non-GAAP operating income of $785 million representing a non-GAAP operating margin of 21.4% in the first quarter of 2023. The increase in non-GAAP operating margin in the first quarter of 2024 was mainly impacted by an increase in non-GAAP gross profit margin, partially offset by higher S&M expenses as a percentage of revenues.
Financial expenses, net in the first quarter of 2024 were $250 million, mainly comprised of net-interest expenses of $233 million. In the first quarter of 2023, financial expenses, net were $260 million, mainly comprised of net-interest expenses of $236 million.
In the first quarter of 2024, we recognized a tax benefit of $52 million, on a pre-tax loss of $467 million. In the first quarter of 2023, we recognized a tax benefit of $19 million, on a pre-tax loss of $272 million. Our tax rate for the first quarter of 2024 was mainly affected by deferred tax benefits resulting from Intellectual Property ("IP")- related integration plans. Such integration plans have been adopted, among others, in an effort of addressing the global adoption of the Organization for Economic Co-operation and Development (OECD) Pillar Two minimum effective corporate tax, commencing in 2024.
Tax rate in the first quarter of 2024 was 11.1%, compared to 7.1% in the first quarter of 2023. Our tax rate for the first quarter of 2024 was mainly affected by deferred tax benefits resulting from intellectual property related integration plans. Non-GAAP tax rate in the first quarter of 2024 was 15.0%, compared to 15.5% in the first quarter of 2023. Our non-GAAP tax rate in the first quarter of 2024 was mainly affected by deferred tax benefits resulting from IP-related integration plans, the generation of profits in various jurisdictions with different tax rates, tax benefits in Israel and other countries, as well as infrequent or non-recurring items. Our non-GAAP tax rate in the first quarter of 2023 was mainly affected by the geographic mix of earnings and interest expense disallowances.
We expect our annual non-GAAP tax rate for 2024 to be between 14%-17%, higher than our non-GAAP tax rate for 2023, which was 13%, mainly due to a reduced net tax benefit related to deferred tax resulting from IP-related integration plans in 2024 compared to 2023.
Net loss attributable to Teva and loss per share in the first quarter of 2024 were $139 million and $0.12, respectively, compared to net loss attributable to Teva and loss per share of $220 million and $0.20, respectively, in the first quarter of 2023. The lower net loss in the first quarter of 2024 was mainly due to higher net loss attributable to non-controlling interests, higher gross profit and lower legal settlements and loss contingencies, partially offset by higher other asset impairments, restructuring and other items, as discussed above. Non-GAAP net income attributable to Teva and non-GAAP diluted earnings per share in the first quarter of 2024 were $548 million and $0.48, respectively, compared to $457 million and $0.40, respectively, in the first quarter of 2023.
Net loss attributable to non-controlling interests was $280 million in the first quarter of 2024, compared to a net loss attributable to non-controlling interests of $33 million in the first quarter of 2023. The higher net loss in the first quarter of 2024 was mainly due to higher impairments of tangible assets largely related to the classification of a business in our International Markets segment as held for sale.
Adjusted EBITDA was $1,005 million in the first quarter of 2024, an increase of 12% compared to $899 million in the first quarter of 2023.
As of March 31, 2024 and 2023, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,167 million and 1,158 million, respectively.
Non-GAAP information: net non-GAAP adjustments in the first quarter of 2024 were $688 million. Non-GAAP net income attributable to Teva and non-GAAP diluted EPS for the first quarter of 2024 were adjusted to exclude the following items:
  • Amortization of purchased intangible assets of $152 million, of which $138 million is included in cost of sales and the remaining $14 million in S&M expenses;
  • Impairment of long-lived assets of $679 million primarily, which primarily consisted of $577 million related to the classification of a business in our International Markets segment as held for sale;
  • Legal settlements and loss contingencies of $106 million, which primarily consisted of $64 million attributable to an update to the estimated settlement provision for the Company’s opioid litigation (mainly the effect of the passage of time on the net present value of the discounted payments);
  • Contingent consideration expenses of $79 million primarily consisted of $64 million related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid®);
  • Equity compensation expenses of $28 million;
  • Restructuring expenses of $13 million;
  • Accelerated depreciation of $7 million;
  • Financial expenses of $12 million;
  • Costs related to regulatory actions taken in facilities of $3 million;
  • Other non-GAAP items of $44 million;
  • Items attributable to non-controlling interests of $284 million; and
  • Corresponding tax effects and unusual tax items of $150 million.
We believe that excluding such items facilitates investors’ understanding of our business including underlying performance trends, thereby improving the comparability of our business performance results between reporting periods.
For a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and for additional information, see the tables below and the information included under “Non-GAAP Financial Measures.” Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP.
Cash flow used in operating activities during the first quarter of 2024 was $124 million, compared to $145 million of cash flow used in operating activities in the first quarter of 2023. The lower cash flow used in operating activities in the first quarter of 2024 resulted mainly from higher profit in our Europe segment, partially offset by changes in certain working capital items, including a negative impact from accounts payables.
During the first quarter of 2024, we generated free cash flow of $32 million, which we define as comprising $124 million in cash flow used in operating activities, $295 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program), partially offset by $124 million in cash used for capital investment and $15 million in cash used for acquisition of businesses, net of cash acquired. During the first quarter of 2023, we generated free cash flow of $41 million, which we define as comprising $145 million in cash flow used in operating activities, $323 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $2 million in proceeds from divestitures of businesses and other assets, partially offset by $139 million in cash used for capital investment.
As of March 31, 2024, our debt was $19,643 million, compared to $19,833 million as of December 31, 2023. This decrease was mainly due to $193 million of exchange rate fluctuations. The portion of total debt classified as short-term as of March 31, 2024 was 16% compared to 8% as of December 31, 2023. Our average debt maturity was approximately 5.7 years as of March 31, 2024, compared to 6.0 years as of December 31, 2023.
On May 3, 2024, the terms of our revolving credit facility ("RCF") were amended to update the Company’s maximum permitted leverage ratio under the RCF for certain periods. Under the terms of the RCF, as amended, the Company’s leverage ratio shall not exceed (i) 4.00x in 2024, 2025 and in the first quarter of 2026, (ii) 3.75x in the second, third and fourth quarters of 2026, and (iii) 3.50x in the first quarter of 2027 and onwards. The RCF permits the Company to increase the maximum leverage ratio if it consummates or commences certain material transactions.
Segment Results for the first Quarter of 2024
United States Segment
As part of a recent shift in executive management responsibilities and in line with our Pivot to Growth strategy, commencing January 1, 2024, Canada is reported as part of our International Markets segment and the segment previously known as our “North America” segment is now referred to as our “United States” segment. Prior period amounts were recast to reflect this change.
The following table presents revenues, expenses and profit for our United States segment for the three months ended March 31, 2024 and 2023:

https://preview.redd.it/0tglw4vbr6zc1.png?width=1652&format=png&auto=webp&s=f40a89b74bfb135517ac47f0b4a812d86d99aebf
Revenues from our United States segment in the first quarter of 2024 were $1,725 million, an increase of $48 million, or 3%, compared to the first quarter of 2023. This increase was mainly due to higher revenues from AUSTEDO, and higher revenues from generic products, partially offset by lower revenues from certain innovative products, primarily COPAXONE and BENDEKA®and TREANDA®, as well as from Anda, our distribution business.
Revenues by Major Products and Activities
The following table presents revenues for our United States segment by major products and activities for the three months ended March 31, 2024 and 2023:

https://preview.redd.it/9ibpylwfr6zc1.png?width=1650&format=png&auto=webp&s=79e221478e8607ad46f8fe3f80dd5f23215764ab
* Other revenues in the first quarter of 2023 were higher compared to the first quarter of 2024, mainly due to a reduction in estimated liabilities in connection with ProAir® HFA during the first quarter of 2023 following its discontinuation.
Generic products revenues in our United States segment (including biosimilars) in the first quarter of 2024 were $808 million, an increase of 8% compared to the first quarter of 2023, mainly due to revenues from lenalidomide capsules (the generic version of Revlimid®), partially offset by increased competition to other generic products.
In the first quarter of 2024, our total prescriptions were approximately 314 million (based on trailing twelve months), representing 8.2% of total U.S. generic prescriptions, compared to approximately 312 million (based on trailing twelve months), representing 8.3% of total U.S. generic prescriptions in the first quarter of 2023, all according to IQVIA data.
On February 24, 2024, Alvotech and Teva announced that the FDA approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira®, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis.
On April 16, 2024, Alvotech and Teva announced that the FDA has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. In June 2023, Alvotech and Teva reached a settlement and license agreement with Johnson & Johnson, granting a licensed entry date in the U.S. no later than February 21, 2025.
AJOVY revenues in our United States segment in the first quarter of 2024 were $45 million, flat compared to the first quarter of 2023. In the first quarter of 2024, AJOVY’s exit market share in the United States in terms of total number of prescriptions was 27.4% compared to 24.5% in the first quarter of 2023.
AUSTEDO revenues in our United States segment in the first quarter of 2024 increased by 67%, to $282 million, compared to $170 million in the first quarter of 2023, mainly due to growth in volume including the launch of AUSTEDO XR in May 2023, as well as expanded access for patients and increased investment to support higher demand.
AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023, and became commercially available in the U.S. in May 2023. AUSTEDO XR is a new once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington’s disease, additional to the currently marketed twice-daily AUSTEDO. AUSTEDO XR is protected by ten Orange Book patents expiring between 2031 and 2041.
UZEDY (risperidone) extended-release injectable suspension was approved by the FDA on April 28, 2023 for the treatment of schizophrenia in adults, and was launched in the U.S. in May 2023. UZEDY is a subcutaneous, long-acting formulation of risperidone that controls the steady release of risperidone. UZEDY is protected by nine Orange Book patents expiring between 2025 and 2033. We are moving forward with plans to launch UZEDY in other countries around the world.
BENDEKA and TREANDA combined revenues in our United States segment in the first quarter of 2024 decreased by 26% to $46 million, compared to the first quarter of 2023, mainly due to generic bendamustine products entry into the market. The orphan drug exclusivity that had attached to bendamustine products expired in December 2022.
COPAXONE revenues in our United States segment in the first quarter of 2024 decreased by 58% to $30 million, compared to the first quarter of 2023, mainly due to generic competition and a decrease in glatiramer acetate market share due to availability of alternative therapies. COPAXONE revenues in the first quarter of 2024 were also negatively impacted by an increase in sales allowance due to a non-recurring item.
Anda revenues from third-party products in our United States segment in the first quarter of 2024 decreased by 10% to $381 million, compared to $424 million in the first quarter of 2023, mainly due to lower demand from seasonal and other market conditions. Anda, our distribution business in the United States, distributes generic and innovative medicines and OTC pharmaceutical products from Teva and various third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda is able to compete in the distribution market by maintaining a broad portfolio of products, competitive pricing and delivery throughout the United States.
United States Gross Profit
Gross profit from our United States segment in the first quarter of 2024 was $858 million, an increase of 9% compared to $789 million in the first quarter of 2023.
Gross profit margin for our United States segment in the first quarter of 2024 increased to 49.8%, compared to 47.0% in the first quarter of 2023. This increase was mainly due to a favorable mix of products primarily driven by an increase in revenues from AUSTEDO and lenalidomide capsules (the generic version of Revlimid®), as well as a decrease in our operational costs.
United States Profit
Profit from our United States segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.
Profit from our United States segment in the first quarter of 2024 was $350 million, an increase of 4% compared to $338 million in the first quarter of 2023. This increase was mainly due to higher gross profit, partially offset by higher S&M expenses.
Europe Segment
Our Europe segment includes the European Union, the United Kingdom and certain other European countries.
The following table presents revenues, expenses and profit for our Europe segment for the three months ended March 31, 2024 and 2023:

https://preview.redd.it/m4cnaqwjr6zc1.png?width=1650&format=png&auto=webp&s=d29a29376f622215efb969c1af9fc9bdb0a1a63c
Revenues from our Europe segment in the first quarter of 2024 were $1,272 million, an increase of 7%, or $88 million, compared to the first quarter of 2023. In local currency terms, revenues increased by 4% compared to the first quarter of 2023, mainly due to higher revenues from generic products and AJOVY.
In the first quarter of 2024, revenues from our Europe segment were positively impacted by exchange rate fluctuations of $43 million, including hedging effects, compared to the first quarter of 2023. Revenues in the first quarter of 2024 included $8 million from a positive hedging impact, which is included in “Other” in the table below. Revenues in the first quarter of 2023 included $6 million from a negative hedging impact, which is included in “Other” in the table below.
Revenues by Major Products and Activities
The following table presents revenues for our Europe segment by major products and activities for the three months ended March 31, 2024 and 2023:

https://preview.redd.it/sirwlizmr6zc1.png?width=1656&format=png&auto=webp&s=763b9e060eb705c6d19a11d9c8efa140615b8368
Generic products revenues (including OTC and biosimilar products) in our Europe segment in the first quarter of 2024, were $1,004 million, an increase of 8% compared to the first quarter of 2023. In local currency terms, revenues increased by 5%, mainly due to higher volumes.
AJOVY revenues in our Europe segment in the first quarter of 2024 increased by 42% to $51 million, compared to $36 million in the first quarter of 2023. In local currency terms revenues increased by 40%, mainly due to growth in European countries in which AJOVY had previously been launched.
COPAXONE revenues in our Europe segment in the first quarter of 2024 decreased by 4% to $57 million, compared to the first quarter of 2023. In local currency terms, revenues decreased by 5%, due to price reductions and a decline in volume resulting from competing glatiramer acetate products and availability of alternative therapies.
Respiratory products revenues in our Europe segment in the first quarter of 2024 decreased by 3% to $66 million compared to the first quarter of 2023. In local currency terms, revenues decreased by 5% compared to the first quarter of 2023, mainly due to net price reductions and lower volumes.
Europe Gross Profit
Gross profit from our Europe segment in the first quarter of 2024 was $738 million, an increase of 13% compared to $655 million in the first quarter of 2023.
Gross profit margin for our Europe segment in the first quarter of 2024 increased to 58.0%, compared to 55.3% in the first quarter of 2023. This increase was mainly due to a favorable mix of products as well as a decrease in our operational costs.
Europe Profit
Profit from our Europe segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.
Profit from our Europe segment in the first quarter of 2024 was $423 million, an increase of 22%, compared to $345 million in the first quarter of 2023. This increase was mainly due to higher gross profit, as described above.
International Markets Segment
Our International Markets segment includes all countries in which we operate other than the United States and countries included in our Europe segment. As part of a recent shift in executive management responsibilities, commencing January 1, 2024, Canada is reported under our International Markets segment and is no longer included as part of our United States segment. Prior period amounts were recast to reflect this change.
The countries in our International Markets segment include highly regulated, mainly generic markets, such as Canada and Israel, branded generics-oriented markets, such as Russia and certain Latin America markets and hybrid markets, such as Japan.
The following table presents revenues, expenses and profit for our International Markets segment for the three months ended March 31, 2024 and 2023:

https://preview.redd.it/q5y53mcqr6zc1.png?width=1646&format=png&auto=webp&s=156ac05a7358272308c626694ba7c4cfac1a2db8
Revenues from our International Markets segment in the first quarter of 2024 were $597 million, an increase of 3% compared to the first quarter of 2023. In local currency terms, revenues increased by 17% compared to the first quarter of 2023, mainly due to higher revenues from generic products in most markets, partially offset by regulatory price reductions and generic competition to off-patented products in Japan.
In the first quarter of 2024, revenues were negatively impacted by exchange rate fluctuations of $82 million, net of hedging effects, compared to the first quarter of 2023. Revenues in the first quarter of 2024 included $4 million from a positive hedging impact, compared to a minimal hedging impact in the first quarter of 2023, which are included in “Other” in the table below.
Revenues by Major Products and Activities
The following table presents revenues for our International Markets segment by major products and activities for the three months ended March 31, 2024 and 2023:

https://preview.redd.it/89uw2u7tr6zc1.png?width=1660&format=png&auto=webp&s=037437b5ca242a624dd9514bedb61cd1cf0c61c9
Generic products revenues (including OTC products) in our International Markets segment were $477 million in the first quarter of 2024, flat compared to the first quarter of 2023. In local currency terms, revenues increased by 16% compared to the first quarter of 2023, mainly due to higher revenues in most markets, largely driven by price increases as a result of higher costs due to inflationary pressure and higher volumes, partially offset by regulatory price reductions and generic competition to off-patented products in Japan.
AJOVY was launched in certain markets in our International Markets segment, including in Canada, Japan, Australia, Israel, South Korea, Brazil and others. We are moving forward with plans to launch AJOVY in other markets. AJOVY revenues in our International Markets segment in the first quarter of 2024 were $17 million, compared to $13 million in the first quarter of 2023.
COPAXONE revenues in our International Markets segment in the first quarter of 2024 were $12 million compared to $17 million in the first quarter of 2023.
AUSTEDO was launched in China and Israel in 2021 and in Brazil in 2022, for the treatment of chorea associated with Huntington’s disease and for the treatment of tardive dyskinesia. In February 2024, we announced a strategic partnership for the marketing and distribution of AUSTEDO in China. We continue with additional submissions in various other markets.
International Markets Gross Profit
Gross profit from our International Markets segment in the first quarter of 2024 was $297 million, an increase of 4% compared to $285 million in the first quarter of 2023.
Gross profit margin for our International Markets segment in the first quarter of 2024 increased to 49.7%, compared to 49.0% in the first quarter of 2023. This increase was mainly due to price increases largely as a result of inflationary pressures and a favorable mix of products, partially offset by regulatory price reductions and generic competition to off-patented products in Japan, as well as higher costs due to inflationary and other macroeconomic pressures.
International Markets Profit
Profit from our International Markets segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.
Profit from our International Markets segment in the first quarter of 2024 was $117 million, an increase of 8%, compared to $108 million in the first quarter of 2023.
Other Activities
We have other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Our other activities are not included in our United States, Europe or International Markets segments described above.
On January 31, 2024, we announced that we intend to divest our API business (including its R&D, manufacturing and commercial activities) through a sale, which divestment is expected to be completed in the first half of 2025. The intention to divest is in alignment with our Pivot to Growth strategy. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or that a divestiture will be agreed or completed at all.
Revenues from other activities in the first quarter of 2024 were $225 million, an increase of 3% in U.S. dollars, or 2% in local currency terms compared to the first quarter of 2023.
API sales to third parties in the first quarter of 2024 were $128 million, reflecting an increase of 2% in both U.S. dollars and local currency terms, compared to the first quarter of 2023, following a reallocation of an immaterial business within our other activities, in line with our intention to divest our API business.

FULL RELEASE: https://www.businesswire.com/news/home/20240508490531/en/
submitted by HotSarcasm to TevaPharmaceutical [link] [comments]


2024.05.03 02:38 Intelligent-Mud9251 Stocked

Stocked
Sortes
submitted by Intelligent-Mud9251 to bud_n_pill_lovers [link] [comments]


2024.05.03 00:14 Intelligent-Mud9251 Temazepam 20mg

Temazepam 20mg
Tried these for the first time and man oh man double the strength off valliums
submitted by Intelligent-Mud9251 to bud_n_pill_lovers [link] [comments]


2024.04.30 15:10 Life123456 I cant tell what type of PREP I have

I take PREP via the 211 method because I only have unprotected sex (top) like 4 to 6 times a year. (I need a bf and am sick of hookups as you can see)
Problem is, PREP 211 is trusted with Truvada but not Descovy quite yet. My PREP seems to be generic, so I can't tell what brand it is.
The bottle says "emtricitabine and Tenofovir Disoproxill Fumarate Tablets" 200 mg/300 MG. From the company Teva.
Is this PREP safe for 2-1-1?
submitted by Life123456 to askgaybros [link] [comments]


2024.04.29 23:25 No-Satisfaction-8979 These aren't pressies although one guy seems to think my gg bars are fake lol.. they aren't. Some random klonz, Xan and Flexeril here.. boutta drop up

These aren't pressies although one guy seems to think my gg bars are fake lol.. they aren't. Some random klonz, Xan and Flexeril here.. boutta drop up submitted by No-Satisfaction-8979 to arethesepressies [link] [comments]


2024.04.28 23:26 Hot_Tadpole1733 Combo mixture

Combo mixture submitted by Hot_Tadpole1733 to bud_n_pill_lovers [link] [comments]


2024.04.28 06:22 ReportsStack Buccal Drug Delivery Systems Market Size, Industry Trends & Growth Analysis from 2024 to 2030

The global buccal drug delivery systems market was valued at approximately USD 3 billion in 2020 and is projected to experience a notable compound annual growth rate (CAGR) exceeding 9% during the forecast period to 2027. A key driver of this growth is the rising population of geriatric patients, alongside an increasing demand for convenient drug delivery methods. Moreover, the growing preference for buccal drug delivery systems, coupled with ongoing research and development efforts in the field, are anticipated to further propel market expansion throughout the forecast period.
To know more about this study, request a free sample report @ https://www.researchcorridor.com/request-sample/?id=54366
Market Trends:
· Growing Preference for Non-Invasive Drug Delivery: There is a rising preference for non-invasive drug delivery methods among patients and healthcare providers. Buccal drug delivery systems offer a non-invasive route of administration, avoiding the need for injections or swallowing pills. This trend is driving the adoption of buccal drug delivery systems, particularly for patients who have difficulty swallowing or are averse to needles.
· Expansion of Drug Formulation and Delivery Technologies: Advancements in drug formulation and delivery technologies are expanding the capabilities of buccal drug delivery systems. Novel formulations such as mucoadhesive films, gels, and tablets are being developed to improve drug absorption and bioavailability through the buccal mucosa. Additionally, innovative delivery devices and technologies, such as patches and sprays, are enhancing the ease of administration and patient compliance.
· Increasing Focus on Patient-Centric Healthcare: There is a growing emphasis on patient-centric healthcare, with healthcare providers prioritizing treatments that offer convenience, comfort, and improved quality of life for patients. Buccal drug delivery systems align with this trend by providing a convenient and patient-friendly alternative to traditional drug delivery methods. This trend is driving the development of patient-friendly buccal dosage forms and user-friendly delivery devices.
· Expanding Applications in Chronic Disease Management: Buccal drug delivery systems are finding expanding applications in the management of chronic diseases such as diabetes, cardiovascular diseases, and neurodegenerative disorders. These systems offer controlled and sustained drug release, allowing for better disease management and improved patient outcomes. As the prevalence of chronic diseases continues to rise globally, the demand for effective and patient-friendly drug delivery systems like buccal delivery is expected to increase.
Market Opportunities:
The buccal drug delivery systems market offers significant opportunities for growth and innovation. Firstly, there is a growing demand for non-invasive drug delivery methods among patients and healthcare providers, presenting an opportunity for the expansion of buccal drug delivery systems. Additionally, advancements in drug formulation and delivery technologies enable the development of novel buccal dosage forms with improved drug absorption and bioavailability, further driving market growth. Moreover, the increasing focus on patient-centric healthcare creates opportunities for the development of patient-friendly buccal drug delivery systems that offer convenience, comfort, and improved treatment adherence. Expanding applications in chronic disease management, particularly for conditions requiring controlled and sustained drug release, present another avenue for market expansion.
According to the recent report published by RC Market Analytics, the Global Buccal Drug Delivery Systems Market is expected to provide sustainable growth opportunities during the forecast period from 2023 to 2030. This latest industry research study analyzes the buccal drug delivery systems market by various product segments, applications, regions and countries while assessing regional performances of numerous leading market participants. The report offers a holistic view of the buccal drug delivery systems industry encompassing numerous stakeholders including raw material suppliers, providers, distributors, consumers and government agencies, among others. Furthermore, the report includes detailed quantitative and qualitative analysis of the global market considering market history, product development, regional dynamics, competitive landscape, and key success factors (KSFs) in the industry.
Browse the Full Report Discretion @ https://www.researchcorridor.com/buccal-drug-delivery-systems-market/
Geographically, the buccal drug delivery systems market report comprises dedicated sections centering on the regional market revenue and trends. The buccal drug delivery systems market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Buccal drug delivery systems market estimates have also been provided for the historical years 2020 & 2021 along with forecast for the period from 2023 - 2030.The report includes a deep-dive analysis of key countries including the U.S., Canada, the U.K., Germany, France, Italy, China, Japan, India, Australia, Mexico, Brazil and South Africa, among others. Thereby, the report identifies unique growth opportunities across the world based on trends occurring in various developed and developing economies.
The Buccal Drug Delivery Systems Market Segmentation:
By Type:
By Application:
By End-User:
By Region:
Key players in the global buccal drug delivery systems market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Indivior Pharmaceuticals, GlaxoSmithKline plc., and Catalent, Inc. These companies are strategically navigating the market landscape through various approaches such as expansion, new investments, the introduction of innovative services, and collaboration. In their pursuit of a competitive edge, these entities are venturing into new geographical regions via both expansion and acquisition, aiming to harness joint synergies and bolster their market positions.
To know more about this study, request a free sample report @ https://www.researchcorridor.com/request-sample/?id=54366
Key Questions Answered by Buccal Drug Delivery Systems Market Report:
About Us: RC Market Analytics is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities to optimize strategies. Our expert’s team of analysts’ provides enterprises with strategic insights. RC Market Analytics works to help enterprises grow through strategic insights and actionable solutions. Feel free to contact us for any report customization at sales@researchcorridor.com.

Media Contact:
Company Name: RC Market Analytics Pvt. Ltd. Contact Person: Vijendra Singh Email: sales@researchcorridor.com Visit us: https://www.researchcorridor.com/
submitted by ReportsStack to u/ReportsStack [link] [comments]


http://swiebodzin.info